{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:52:29Z","timestamp":1770079949582,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Continuation of bevacizumab plus second\u2010line chemotherapy has significantly improved overall and progression\u2010free survival in patients with metastatic colorectal cancer (mCRC). However, the cost\u2010effectiveness of such high cost therapy is still uncertain in China; so this analysis was performed to evaluate the cost\u2010effectiveness of these treatment options from the Chinese health care system perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cost\u2010effectiveness analysis was conducted using data from the ML18147 trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier NCT00700102) by modeling a partitioned survival model. Main evaluation indicators were quality\u2010adjusted life years (QALYs) and incremental cost\u2010effectiveness ratio (ICER) with a willingness to pay (WTP) threshold of $38,201 per QALY. One\u2010way and probabilistic sensitivity analyses were conducted to assess the robustness and stability of the model. Subgroup and scenario analyses were also performed to make our study more relevant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Bevacizumab plus chemotherapy increased 0.12 QALYs and an incremental cost of $22,761.62 compared with chemotherapy, resulting in an ICER of $188,904.09 per QALY. The model was most sensitive to the utility of progression\u2010free survival and the cost of bevacizumab. Compared with chemotherapy, bevacizumab plus chemotherapy had a 0% cost\u2010effectiveness probability, and no cost\u2010effectiveness in subgroups at the WTP threshold of $38,201 per QALY. The scenario analysis found that bevacizumab biosimilar gained an ICER of $126,397.38 per QALY when assuming the cost of drugs was calculated at the most affordable price.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>At the WTP threshold of $38,201 per QALY, continuation of bevacizumab plus chemotherapy is unlikely considered cost\u2010effective for patients after first progression of mCRC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6904","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:29:04Z","timestamp":1704702544000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2010effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer"],"prefix":"10.1002","volume":"13","author":[{"given":"Yulian","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rufu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxing","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-5447","authenticated-orcid":false,"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Affiliated Hospital of Army Medical University  Chongqing People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Cancer Today. Accessed April 18 2023.https:\/\/gco.iarc.fr\/today\/home"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.02.002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095277"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.019"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147717"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network.NCCN Guidelines for Treatment of Cancer by Site: Colon Cancer.2022. Accessed January 28 2023.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.01.07"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7826"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4904"},{"key":"e_1_2_9_13_1","unstructured":"Chinese drug.Chinese Drug Price of Drug Centralized Bid Procurement.2022. Accessed January 28 2023.https:\/\/db.yaozh.com\/yaopinzhongbiao"},{"key":"e_1_2_9_14_1","unstructured":"Chinese Healthcare Security Administration.Notice of the Chinese Central Committee and the State Council on the Issuance of the 13th Five\u2010Year Plan for eepening the Health Care System Reform. Accessed May 6 2023.http:\/\/www.nhsa.gov.cn\/art\/2016\/12\/27\/art_53_1166.html"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1095398"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820902271"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651299"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02114-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_2_9_20_1","unstructured":"National Bureau of Statistics of China.National Bureau of Statistics of China.2022. Accessed March 30 2023.http:\/\/data.stats.gov.cn\/english\/index.htm"},{"key":"e_1_2_9_21_1","unstructured":"GetData.Graph Digitizer. Accessed January 20 2023.http:\/\/www.getdata\u2010graph\u2010digitizer.com\/index.php"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.013"},{"key":"e_1_2_9_23_1","unstructured":"Chinese Bureau of Disease Control and Prevention.Report on the Nutrition and Chronic Diseases Status of Chinese Residents.2020.https:\/\/xueshu.baidu.com\/usercenter\/paper\/show?paperid=1t7y08h0d55t0cw0p73x0ev087731730&site=xueshu_se&hitarticle=1"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.08.015"},{"key":"e_1_2_9_25_1","unstructured":"Shanghai Municipal Development and Reform Commission Shanghai Municipal Health Commission.Compilation of Medical Service Items and Prices of Medical Institutions in Shanghai. Accessed March 31 2023.https:\/\/wsjkw.sh.gov.cn\/ylsfbz\/index.html"},{"key":"e_1_2_9_26_1","unstructured":"Beijing Municipal Medical Insurance Bureau.Medical Service Price Inquiry. Accessed March 31 2023.http:\/\/ybj.beijing.gov.cn\/2020_zwfw\/2020_bmcx\/202002\/P020211231647015053723.xls"},{"key":"e_1_2_9_27_1","unstructured":"Chongqing Medical Security Bureau.Notice on Printing and Distributing the Catalogue of Medical Service Items of Chongqing Basic Medical Insurance. Accessed March 31 2023.https:\/\/ylbzj.cq.gov.cn\/zwgk_535\/zfxxgkml\/zcwj_291934\/gfxwj\/202107\/t20210730_9529468.html"},{"key":"e_1_2_9_28_1","unstructured":"Changsha Healthcare Security Administration.Price List of Current Medical Service Prices in Changsha.2020. Accessed March 31 2023.http:\/\/www.tianxin.gov.cn\/zwgk8\/bmxxgkml\/qylbzj\/zcwj15\/gzzd51\/202009\/P020200915588540967098.pdf"},{"key":"e_1_2_9_29_1","unstructured":"Shenyang Department of Human Resources and Social Security.Shenyang Finance Department. Notice on Printing and Distributing Price of Medical Service Projects of Public Medical Institutions in Shenyang. Accessed March 31 2023.http:\/\/wjw.shenyang.gov.cn\/zwgk\/fdzdgknr\/cwxx\/202208\/t20220803_3794467.html"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-022-01112-1"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06816-x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2020.07.580"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.1.1.37"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X98018002S09"},{"key":"e_1_2_9_35_1","unstructured":"National Medical Products Administration.National Medical Products Administration Data Search. Accessed May 6 2023.https:\/\/www.nmpa.gov.cn\/datasearch\/search\u2010result.html"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211038929"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100060"},{"key":"e_1_2_9_38_1","unstructured":"National Healthcare Security Administration of China.Report on the Construction of a Rule of Law Government by the National Healthcare Security Administration in 2022. Accessed May 7 2023.http:\/\/www.nhsa.gov.cn\/art\/2023\/3\/31\/art_123_10317.html"},{"key":"e_1_2_9_39_1","unstructured":"National Healthcare Security Administration of China.Response of the National Healthcare Security Administration to Motion No. 6450 of the 3rd Session of the 13th National People's Congress. Accessed May 7 2023.http:\/\/www.nhsa.gov.cn\/art\/2020\/10\/9\/art_110_6873.html"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0325-9"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T10:22:35Z","timestamp":1714126955000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cam4.6904"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6904","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6904"}}